Breaking News Instant updates and real-time market news.

RHHBY

Roche

$0.00

(0.00%)

09:09
12/07/19
12/07
09:09
12/07/19
09:09

Genentech announces new data on CD20-CD3 T-cell in Hodgkin's lymphoma

Genentech, a member of the Roche Group, announced new data on two investigational CD20-CD3 T-cell engaging bispecific antibodies, mosunetuzumab and CD20-TCB, in people with relapsed or refractory B-cell non-Hodgkin's lymphoma. Results from the Phase I/Ib GO29781 study of mosunetuzumab, including data from people previously treated with chimeric antigen receptor T-cell therapy, will be presented at the 61st American Society of Hematology 2019 Annual Meeting. The GO29781 study evaluated mosunetuzumab in patients with R/R NHL, including patients who have relapsed following, or are resistant to, CAR T-cell therapy. Results from this dose-escalation study showed "encouraging efficacy" with an objective response rate of 62.7% in slow-growing NHL and 37.1% in aggressive NHL. Additionally, data demonstrated a complete response rate of 43.3% in slow-growing NHL and 19.4% in aggressive NHL. CRs showed durability, with 82.8% of patients with slow-growing NHL remaining in remission up to 26 months off initial treatment and 70.8% of patients with aggressive NHL, remaining in remission up to 16 months off initial treatment, the company added. Of the participants who received prior CAR T-cell therapy, the ORR was 38.9%, and 22.2% achieved a CR. Adverse reactions included cytokine release syndrome in 28.9% of patients with 20.0% at Grade 1 and 1.1% at Grade 3. Grade 3 neurological adverse events occurred in 3.7% of patients, Genentech said.

  • 07

    Dec

  • 09

    Dec

  • 10

    Dec

  • 16

    Dec

RHHBY Roche
$0.00

(0.00%)

11/01/19
LEER
11/01/19
NO CHANGE
Target $26
LEER
Outperform
Dicerna price target raised to $26 from $22 at SVB Leerink
SVB Leerink analyst Mani Foroohar raised his price target for Dicerna Pharmaceuticals (DRNA) to $26 from $22 saying the terms for the company's partnership with Roche (RHHBY) to develop and commercialize DCR-HBVS are "quite favorable." Dicerna will receive a $200M upfront payment, up to $1.47B in potential milestones, and up to mid-teens royalties on future sales. The transaction is "meaningfully validating" for Dicerna's strategy for large population indications, Foroohar tells investors in a research note. With shares trading at an implied enterprise value "materially below" the pre-deal value, investors should begin to appreciate the scope of the potential partnership opportunities, says the analyst. He keeps an Outperform rating on Dicerna.
11/01/19
HCWC
11/01/19
NO CHANGE
Target $22
HCWC
Buy
Dicerna HBV deal earlier, on better terms than expected, says H.C. Wainwright
H.C. Wainwright analyst Ed Arce affirmed his Buy rating on Dicerna Pharmaceuticals (DRNA) shares after the companpy announced a collaboration and licensing agreement with Roche (RHHBY) for the worldwide development and commercialization the company's lead asset for the treatment of hepatitis B virus, or HBV. While he has long anticipated "a large HBV deal," the collaboration with Roche is earlier, and with better economics, than Arce had expected, the analyst tells investors. He maintains a $22 price target on Dicerna shares.
11/14/19
WBLR
11/14/19
INITIATION
WBLR
Market Perform
William Blair says Ionis fairly valued on Spinraza headwinds
William Blair analyst Myles Minter initiated coverage of Ionis Pharmaceuticals with a Market Perform rating and $58 fair value estimate. Spinraza, which is marketed by Biogen (BIIB), generates about $2B in revenue per year and has revolutionized the treatment of spinal muscular atrophy, but its long-term growth potential faces headwinds, Minter tells investors in a research note. The analyst anticipates the recent approval of Novartis's (NVS) Zolgensma, an SMA gene therapy, will erode Spinraza's market share of new-start type-1 SMA patients. But more concerning, according to Minter, is the potential 2020 U.S. approval of Roche's (RHHBY) risdiplam, which he believes could erode Spinraza's total market share of type-2/3 patients given a more favorable oral route of delivery. The analyst sees Ionis shares as fairly valued at current levels given the near-term headwinds for its commercial franchise.
11/19/19
LEER
11/19/19
NO CHANGE
Target $30
LEER
Outperform
Dicerna price target raised to $30 from $26 at SVB Leerink
SVB Leerink analyst Mani Foroohar raised his price target for Dicerna (DRNA) to $30 from $26 and maintained an Outperform rating after the company announced a collaboration with Novo Nordisk (NVO) to develop candidates for liver-related cardiometabolic diseases. In a research note to investors, Foroohar says that while Dicerna's stock has traded up about 30% since the announcement of a partnership with Roche (RHHBY), it remains undervalued.

TODAY'S FREE FLY STORIES

LIZI

Lizhi

$0.00

(0.00%)

10:26
01/17/20
01/17
10:26
01/17/20
10:26
Syndicate
Lizhi opens at $11.03, IPO priced at $11.00 per share »

Lizhi (LIZI) priced 4.1M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
Wolfe Research tech strategist to hold an analyst/industry webcast »

Tech Strategist…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
UBS services analysts to hold an analyst/industry conference call »

Services Analyst Lasser,…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
Wolfe Research industrials analysts to hold an analyst/industry webcast »

Multi-Idndustry Analyst…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
JPMorgan U.S. telecom & semis analysts hold an analyst/industry conference call »

U.S. Telecom &…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
Cowen Washington policy strategist to hold an analyst/industry conference call »

Washington Policy…

MIDD

Middleby

$111.11

1.51 (1.38%)

, MCD

McDonald's

$212.00

1.14 (0.54%)

10:24
01/17/20
01/17
10:24
01/17/20
10:24
Recommendations
Middleby, McDonald's, Welbilt analyst commentary  »

Middleby equimpment may…

MIDD

Middleby

$111.11

1.51 (1.38%)

MCD

McDonald's

$212.00

1.14 (0.54%)

WBT

Welbilt

$15.39

-0.06 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

CMS

CMS Energy

$65.31

-0.07 (-0.11%)

10:24
01/17/20
01/17
10:24
01/17/20
10:24
Downgrade
CMS Energy rating change  »

CMS Energy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 12

    Mar

  • 13

    Mar

ES

Eversource

$87.64

-0.09 (-0.10%)

10:24
01/17/20
01/17
10:24
01/17/20
10:24
Downgrade
Eversource rating change  »

Eversource downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

NEE

NextEra Energy

$252.14

-0.13 (-0.05%)

10:23
01/17/20
01/17
10:23
01/17/20
10:23
Downgrade
NextEra Energy rating change  »

NextEra Energy downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

STT

State Street

$85.19

4.185 (5.17%)

10:22
01/17/20
01/17
10:22
01/17/20
10:22
Hot Stocks
State Street management 'confident in capital position' »

Comment from Q4 earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 31

    Jan

  • 26

    Feb

10:20
01/17/20
01/17
10:20
01/17/20
10:20
Conference/Events
Wolfe Research energy analysts to hold an analyst/industry luncheon »

Energy Analysts…

GLD

SPDR Gold Shares

$146.63

0.33 (0.23%)

10:20
01/17/20
01/17
10:20
01/17/20
10:20
Options
Gold ETF call volume surges on March spread »

Gold ETF call volume…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOLS

Evolus

$11.43

0.25 (2.24%)

10:19
01/17/20
01/17
10:19
01/17/20
10:19
Recommendations
Evolus analyst commentary  »

Evolus shares offer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VEL

Velocity Financial

$0.00

(0.00%)

10:18
01/17/20
01/17
10:18
01/17/20
10:18
Syndicate
Breaking Syndicate news story on Velocity Financial »

Velocity Financial opens…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
01/17/20
01/17
10:17
01/17/20
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
01/17/20
01/17
10:16
01/17/20
10:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
01/17/20
01/17
10:15
01/17/20
10:15
General news
FX Action: The dollar »

FX Action: The dollar was…

10:15
01/17/20
01/17
10:15
01/17/20
10:15
General news
U.S. JOLTS reported job openings dropped -561k to 6,800k in November »

U.S. JOLTS reported job…

MDLA

Medallia

$31.67

-0.26 (-0.81%)

, GWB

Great Western

$34.30

-0.06 (-0.17%)

10:14
01/17/20
01/17
10:14
01/17/20
10:14
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

MDLA

Medallia

$31.67

-0.26 (-0.81%)

GWB

Great Western

$34.30

-0.06 (-0.17%)

TTEC

TTEC Holdings

$42.81

0.4 (0.94%)

BGNE

BeiGene

$169.94

2.055 (1.22%)

AMED

Amedisys

$181.47

0.28 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 28

    Jan

  • 04

    Feb

  • 27

    Feb

MS

Morgan Stanley

$56.87

0.42 (0.74%)

, TWTR

Twitter

$34.39

0.2 (0.58%)

10:14
01/17/20
01/17
10:14
01/17/20
10:14
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

MS

Morgan Stanley

$56.87

0.42 (0.74%)

TWTR

Twitter

$34.39

0.2 (0.58%)

EBAY

eBay

$35.70

-0.21 (-0.58%)

CAKE

Cheesecake Factory

$39.21

-1.3 (-3.21%)

IBM

IBM

$137.21

-0.79 (-0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

  • 28

    Jan

  • 06

    Feb

  • 12

    Feb

WDC

Western Digital

$68.29

-0.33 (-0.48%)

, QCOM

Qualcomm

$93.76

1.99 (2.17%)

10:14
01/17/20
01/17
10:14
01/17/20
10:14
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

WDC

Western Digital

$68.29

-0.33 (-0.48%)

QCOM

Qualcomm

$93.76

1.99 (2.17%)

PINS

Pinterest

$23.36

0.4 (1.74%)

SNAP

Snap

$19.04

0.79 (4.33%)

YUM

Yum! Brands

$104.59

2.43 (2.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

  • 04

    Feb

  • 05

    Feb

  • 06

    Feb

VEL

Velocity Financial

$0.00

(0.00%)

10:14
01/17/20
01/17
10:14
01/17/20
10:14
Syndicate
Velocity Financial indicated to open at $13.70, IPO priced at $13.00 »

Velocity Financial (VEL)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

SNV

Synovus

$39.86

0.24 (0.61%)

10:12
01/17/20
01/17
10:12
01/17/20
10:12
Conference/Events
Synovus management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

  • 25

    Feb

  • 26

    Feb

PWFL

PowerFleet

$8.20

-0.04 (-0.49%)

10:10
01/17/20
01/17
10:10
01/17/20
10:10
Conference/Events
PowerFleet management to meet with Barrington »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.